List view / Grid view
30 September 2013 | By Roche
Use of new Herceptin formulation reduced the time needed for pharmacists and doctors to treat patients...
30 September 2013 | By Boehringer Ingelheim
LUME-Lung 1 Phase III clinical trial showed that the novel investigational compound nintedanib* provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer...
28 September 2013 | By Roche
Kadcyla nearly doubled the time that patients lived without their disease worsening compared with treatment of physician’s choice...
28 September 2013 | By Merck
Merck Animal Health is proud to support canine rabies vaccination programs in some of the most at-risk regions in the world...
28 September 2013 | By Amgen
Trial evaluated nearly 1,000 patients with metastatic colorectal cancer...
27 September 2013 | By Johnson & Johnson
Japan is the first country in the world where SOVRIAD™ is approved...
27 September 2013 | By Novo Nordisk
Data from the DUAL™ I trial show IDegLira demonstrates a statistically significant greater reduction in blood sugar levels (HbA1c) compared to insulin degludec or liraglutide alone...
27 September 2013 | By Novartis
Pivotal myopic CNV trials with Lucentis® (ranibizumab) show visual acuity improvement of nearly 14 letters with a median of two injections at one year...
27 September 2013 | By GlaxoSmithKline
GlaxoSmithKline (GSK) and Barclays have formed a new partnership which aims to increase access to affordable healthcare and medicines for people in Zambia...
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced today that veterinarians and farmers across the globe have reached the milestone of protecting more than 500 million pigs from the potentially devastating consequences of Mycoplasma hyopneumonia...
27 September 2013 | By AstraZeneca
AstraZeneca today announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for olaparib...
27 September 2013 | By Cancer Research UK
A US-led initiative to map the molecular similarities and differences of thousands of tumours has revealed new ways to classify cancer...
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has inaugurated the building of its chemicals R&D laboratory Center of Competence in the Zhangjiang High-Tech Park in Shanghai...
27 September 2013 | By Genzyme
18 platform and poster presentations provide deeper insight into the Clinical Development Programs for Aubagio® and Lemtrada™...
27 September 2013 | By Gilead Sciences, Inc.
Tybost™ is a new Bbosting agent for HIV therapy which facilitates once-daily dosing of the protease inhibitors Atazanavir and Darunavir...
